Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
$1.18
$0.07(1.75%)
At close: 4:00 PM EST
$1.18
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $4.43
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$89.09M
Enterprise Value$26.87M
Total Cash (Recent Filing)$46.64M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Apr 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding70,703,636
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.74
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$7.80Price Target Upside561.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySustained increases in endogenous insulin markers and meaningful blood sugar reductions in difficult-to-treat type 2 diabetes patients support a potential disease-modifying profile for the lead candidate.
Combination Potential With GLP-1 TherapiesPreclinical data showing improved glycemic control, greater weight reduction, and preservation of lean mass when combined with GLP-1 receptor agonists suggest attractive combination strategies.
Pipeline ExpansionAdvancement of a next-generation metabolic candidate into early human testing combined with planned confirmatory studies broadens development pathways and increases therapeutic opportunities.
Bears Say
Clinical And Regulatory Execution RiskCompany value depends heavily on successful execution of upcoming confirmatory trials and regulatory alignment, creating substantial clinical and approval risk.
Financing OverhangPersistent financing needs and an expected overhang from recent capital raises could pressure share sentiment and restrict financial flexibility.
Higher Operating Costs And DilutionElevated operating expenses and dilution from recent fundraising have prompted lower analyst valuation assumptions, weighing on the fundamental outlook.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $4.43 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $89.09M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Apr 06, 2026 which is in 65 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Nov 04, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.014.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 70,703,636 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went up 6.349%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.80 (561.02% Upside)
$7.80 (561.02% Upside)
Hedge Fund Trend
Decreased
By 443.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $196.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-209.00%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.80
▲(561.02% Upside)
Technical Analysis
Ownership Overview
8.85% Insiders
9.92% Mutual Funds
15.05% Other Institutional Investors
62.60% Public Companies and
Individual Investors